this invention relates to pharmaceutical combinations of a cholesteryl ester transfer protein inhibitor or a pharmaceutically acceptable salt thereof ; and an antihypertensive agent or a pharmaceutically acceptable salt thereof , optionally in combination with an hmg coa reductase inhibitor or a pharmaceutically acceptable salt thereof , kits containing such combinations and methods of using such combinations to treat subjects suffering from atherosclerosis , peripheral vascular disease , dyslipidemia , hyperbetaliproteinemia , hypoalphalipoproteinemia , hypercholesterolemia , hypertriglyceridemia , familial - hypercholesterolemia , cardiovascular disorders , angina , ischemia , cardiac ischemia , stroke , myocardial infarction , reperfusion injury , angioplastic restenosis , hypertension , vascular complications of diabetes , obesity or endotoxemia in a mammal .